ZA867767B - Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect,and formulations thus obtained - Google Patents

Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect,and formulations thus obtained

Info

Publication number
ZA867767B
ZA867767B ZA867767A ZA867767A ZA867767B ZA 867767 B ZA867767 B ZA 867767B ZA 867767 A ZA867767 A ZA 867767A ZA 867767 A ZA867767 A ZA 867767A ZA 867767 B ZA867767 B ZA 867767B
Authority
ZA
South Africa
Prior art keywords
formulations
polyethylene glycol
active substance
solution
micronized
Prior art date
Application number
ZA867767A
Other languages
English (en)
Inventor
Massimo Calanchi
Piergiorgio Dr Rossi
Original Assignee
Eurand Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Spa filed Critical Eurand Spa
Publication of ZA867767B publication Critical patent/ZA867767B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
ZA867767A 1985-10-15 1986-10-14 Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect,and formulations thus obtained ZA867767B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22494/85A IT1187751B (it) 1985-10-15 1985-10-15 Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Publications (1)

Publication Number Publication Date
ZA867767B true ZA867767B (en) 1987-06-24

Family

ID=11197023

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA867767A ZA867767B (en) 1985-10-15 1986-10-14 Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect,and formulations thus obtained

Country Status (18)

Country Link
US (1) US4880623A (de)
EP (1) EP0220760B1 (de)
JP (1) JPH0811731B2 (de)
KR (1) KR940006320B1 (de)
AT (1) ATE66367T1 (de)
AU (1) AU590622B2 (de)
CA (1) CA1280976C (de)
DE (1) DE3680989D1 (de)
DK (1) DK168691B1 (de)
ES (1) ES2040209T3 (de)
FI (1) FI87424C (de)
GR (1) GR3003150T3 (de)
HK (1) HK12595A (de)
IT (1) IT1187751B (de)
NO (1) NO172168C (de)
NZ (1) NZ217841A (de)
PT (1) PT83522B (de)
ZA (1) ZA867767B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5215752A (en) * 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1401399A2 (de) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
JP2006518754A (ja) * 2003-02-24 2006-08-17 マリンクロッド・インコーポレイテッド ベンズヒドリルチオアセトアミドの改良製法
ES2233227T1 (es) * 2003-03-26 2005-06-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de ingredientes farmaceuticos activos con un area superficial especifica.
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2462240T3 (es) * 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO98434A (de) * 1959-04-30
US3920809A (en) * 1973-11-05 1975-11-18 Lilly Co Eli Dibenzo(b,d)pyranone dispersions
US3988439A (en) * 1973-11-05 1976-10-26 Eli Lilly And Company Dibenzo[b,d]pyranone dispersions
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (de) * 1977-09-14 1979-04-04 Kanebo, Ltd. Nifedipine enthaltendes Arzneipräparat und Verfahren zu seiner Herstellung.
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ATE66367T1 (de) 1991-09-15
AU590622B2 (en) 1989-11-09
KR870003779A (ko) 1987-05-04
DK168691B1 (da) 1994-05-24
EP0220760B1 (de) 1991-08-21
IT1187751B (it) 1987-12-23
PT83522A (en) 1986-11-01
DK481186D0 (da) 1986-10-08
FI87424C (fi) 1993-01-11
NO172168B (no) 1993-03-08
FI864151A0 (fi) 1986-10-14
JPH0811731B2 (ja) 1996-02-07
NZ217841A (en) 1990-01-29
PT83522B (pt) 1988-11-30
FI87424B (fi) 1992-09-30
ES2040209T3 (es) 1993-10-16
KR940006320B1 (ko) 1994-07-16
NO864060D0 (no) 1986-10-13
JPS62167727A (ja) 1987-07-24
CA1280976C (en) 1991-03-05
EP0220760A3 (en) 1987-09-23
EP0220760A2 (de) 1987-05-06
US4880623A (en) 1989-11-14
AU6383286A (en) 1987-04-16
DK481186A (da) 1987-04-16
FI864151A (fi) 1987-04-16
NO864060L (no) 1987-04-21
GR3003150T3 (en) 1993-02-17
IT8522494A0 (it) 1985-10-15
HK12595A (en) 1995-02-03
DE3680989D1 (de) 1991-09-26
NO172168C (no) 1993-06-16

Similar Documents

Publication Publication Date Title
AU590622B2 (en) Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained
CA1329543C (en) Human growth hormone formulation
DE68916782T2 (de) Enterische formulierungen auf basis physiologisch aktiven peptiden und proteinen.
CA1269328A (en) Transdermal aqueous aryl-propionic-acid derivatives medication and methods of preparing same
AU1211992A (en) Low dose dry pharmaceutical preparations
ATE108647T1 (de) Arzneimittel mit langsamer wirkstofffreisetzung.
CA1124178A (en) Nabilone granulation
JPS5649314A (en) Lasting pharmaceutical composition having prolonged action and its preparation
JPS5726615A (en) Improving method for absorbability of slightly soluble drug
JPS5781409A (en) External plaster
EP0952819B1 (de) Biologisch aktive zusammensetzung
EP0223033B1 (de) Verfahren zum gleichzeitigen Trocknen und Granulieren von Extraktstoffen aus enteiweisstem Kälberblut, nach diesem Verfahren erhaltenes Granulat und dessen Verwendung zur Herstellung von pharmazeutischen Präparaten
JP3202775B2 (ja) 固形製剤
KR0185294B1 (ko) 투명액상 이부프로펜 조성물 및 이를 함유하는 연질캅셀제
JP2007511517A (ja) 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化
Wisudyaningsih et al. IAI SPECIAL EDITION: Effect of gelling agent and penetration enhancer on the release rate of ibuprofen-PEG 6000 solid dispersion from gel preparations
Sallam et al. Dissolution characteristics of interactive powder mixtures. Part two: effect of surface characteristics of excipients
CS234469B1 (cs) Dermální přípravek s obsahem kyseliny vitaminu A